Literature DB >> 33616002

Failure mode and effect analysis in human islet isolation: from the theoretical to the practical risk.

Quentin Perrier1,2, Vanessa Lavallard1, Nadine Pernin1, Charles-Henri Wassmer1, David Cottet-Dumoulin1, Fanny Lebreton1, Kevin Bellofatto1, Axel Andres1, Ekaterine Berishvili1, Domenico Bosco1, Thierry Berney1, Géraldine Parnaud1.   

Abstract

This study aimed to assess the global mapping risk of human islet isolation, using a failure mode and effect analysis (FMEA), and highlight the impact of quality assurance procedures on the risk level of criticality. Risks were scored using the risk priority number (RPN) scoring method. The risk level of criticality was made based on RPN and led to risk classification (low to critical). A raw risk analysis and a risk control analysis (with control means and quality assurance performance) were undertaken. The process of human islet isolation was divided into 11 steps, and 230 risks were identified. Analysis of the highest RPN of each of the 11 steps showed that the 4 highest risks were related to the pancreas digestion and islet purification stages. After implementation of reduction measures and controls, critical and severe risks were reduced by 3-fold and by 2-fold, respectively, so that 90% of risks could be considered as low to moderate. FMEA has proven to be a powerful approach for the identification of weaknesses in the islet isolation processes. The results demonstrated the importance of staff qualification and continuous training and supported the contribution of the quality assurance system to risk reduction.

Entities:  

Keywords:  Pancreatic islet isolation; human islet; manufacturing procedure; quality subject; risk criticality; risk mapping

Mesh:

Year:  2021        PMID: 33616002      PMCID: PMC8018422          DOI: 10.1080/19382014.2020.1856618

Source DB:  PubMed          Journal:  Islets        ISSN: 1938-2014            Impact factor:   2.694


  36 in total

1.  The use of failure mode effect and criticality analysis in a medication error subcommittee.

Authors:  E Williams; R Talley
Journal:  Hosp Pharm       Date:  1994-04

2.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

3.  Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL Network.

Authors:  Sandrine Lablanche; Sophie Borot; Anne Wojtusciszyn; Francois Bayle; Rachel Tétaz; Lionel Badet; Charles Thivolet; Emmanuel Morelon; Luc Frimat; Alfred Penfornis; Laurence Kessler; Coralie Brault; Cyrille Colin; Igor Tauveron; Domenico Bosco; Thierry Berney; Pierre-Yves Benhamou
Journal:  Diabetes Care       Date:  2015-06-11       Impact factor: 19.112

4.  An effective purification method using large bottles for human pancreatic islet isolation.

Authors:  Masayuki Shimoda; Takeshi Itoh; Shuichi Iwahashi; Morihito Takita; Koji Sugimoto; Mazhar A Kanak; Daisuke Chujo; Bashoo Naziruddin; Marlon F Levy; Paul A Grayburn; Shinichi Matsumoto
Journal:  Islets       Date:  2012-11-01       Impact factor: 2.694

Review 5.  Evaluation of the blood compatibility of materials, cells, and tissues: basic concepts, test models, and practical guidelines.

Authors:  Kristina N Ekdahl; Jaan Hong; Osama A Hamad; Rolf Larsson; Bo Nilsson
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

6.  Human islet purification: a prospective comparison of Euro-Ficoll and bovine serum albumin density gradients.

Authors:  D R Chadwick; G S Robertson; H Contractor; S Swift; S Rose; S T Thirdborough; R Chamberlain; R F James; P R Bell; N J London
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

7.  Automated islet isolation from human pancreas.

Authors:  C Ricordi; P E Lacy; D W Scharp
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

8.  Comparison of Clostripain and Neutral Protease as Supplementary Enzymes for Human Islet Isolation.

Authors:  Heide Brandhorst; Paul R Johnson; Johanna Mönch; Manfred Kurfürst; Olle Korsgren; Daniel Brandhorst
Journal:  Cell Transplant       Date:  2018-11-13       Impact factor: 4.064

9.  Human pancreatic islet isolation: Part II: purification and culture of human islets.

Authors:  Meirigeng Qi; Barbara Barbaro; Shusen Wang; Yong Wang; Mike Hansen; Jose Oberholzer
Journal:  J Vis Exp       Date:  2009-05-26       Impact factor: 1.355

10.  National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities.

Authors:  Camillo Ricordi; Julia S Goldstein; A N Balamurugan; Gregory L Szot; Tatsuya Kin; Chengyang Liu; Christine W Czarniecki; Barbara Barbaro; Nancy D Bridges; Jose Cano; William R Clarke; Thomas L Eggerman; Lawrence G Hunsicker; Dixon B Kaufman; Aisha Khan; David-Erick Lafontant; Elina Linetsky; Xunrong Luo; James F Markmann; Ali Naji; Olle Korsgren; Jose Oberholzer; Nicole A Turgeon; Daniel Brandhorst; Xiaojuan Chen; Andrew S Friberg; Ji Lei; Ling-Jia Wang; Joshua J Wilhelm; Jamie Willits; Xiaomin Zhang; Bernhard J Hering; Andrew M Posselt; Peter G Stock; A M James Shapiro; Xiaojuan Chen
Journal:  Diabetes       Date:  2016-07-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.